~60%
Broad eligible population
Approximately 60% of prostate cancer risk is attributable to heritable factors, many of which can be detected as genetic markers by this test.¹
Prostate Cancer Integrated Risk
Combines genetic risk factors identified from whole-genome sequencing with clinical information to predict a person's 10-year and/or remaining lifetime absolute risk of developing prostate cancer.
Why it matters
Risk the standard workup does not capture
Up to 95%
Beyond single-gene screening
Up to 95% of individuals do not have a single-gene prostate cancer condition, but may have genetic risk factors detectable by this test.²
8.6%
Hidden risk detection
Our studies showed 8.6% of men* with no family history of prostate cancer were identified as high risk, with roughly 3× higher prostate cancer incidence compared to the non-risk group.³
1. National Cancer Institute. Genetics of Prostate Cancer — Health Professional Version. Accessed Nov 2025. 2. Tuffaha H, Edmunds K, Fairbairn D, et al. Guidelines for genetic testing in prostate cancer: a scoping review. Prostate Cancer Prostatic Dis. 2024;27:594–603. 3. Internal data on file. *MyOme recognizes and respects the diversity of gender identities. For the purposes of this webpage, "men" is used to refer to individuals assigned male at birth.
What goes into the score
Genetics integrated with clinical risk factors
Genetic risk factors analyzed by WGS:
- ~7M disease risk factors identified in GWAS studies of >850K men with prostate cancer
- Thousands of ancestry markers, producing a cross-ancestry PRS that accurately stratifies risk across diverse populations
Clinical risk factors integrated:
- Current age
- Family history of prostate cancer
Who it's for
Eligibility, turnaround times, and sample types
Eligibility
Individuals aged 30–75 with no personal history of prostate cancer and no pathogenic variant in ATM, BRCA1, BRCA2, CHEK2, HOXB13, MSH2, MLH1, MSH6, PALB2, PMS2, or TP53. For individuals under 40 or over 70, the test reports remaining lifetime risk only.
Turnaround times
From samples received, most results are delivered in 5 to 6 weeks. Follow-up testing or re-requisitions for existing MyOme patients are typically completed in under 2 weeks, often within a few days.
Sample Types Accepted
- Blood
- Buccal (cheek swab)
Test codes
Atlas Cancer PlusPR41034
Atlas Cancer SelectPR42038
Turnaround times are estimates and begin once samples are processed at MyOme. They may be extended in cases outside MyOme's control, including delays related to confirmation testing or other unforeseen circumstances.
Ordering
Two Ordering Options
This test can be ordered as part of the Atlas Cancer Plus or Atlas Cancer Select offerings, depending on your needs.
Atlas Cancer Plus
Whole-genome sequencing for comprehensive insights across coding and non-coding regions.
View the technical one-pagerAtlas Cancer Select
High-coverage exome plus low-coverage whole-genome sequencing — a cost-effective option for preventative health decisions.
View the technical one-pagerInterpreting results
Implications for prevention
Increased risk results can inform proactive recommendations aligned with clinical guidelines, such as healthy lifestyle habits, earlier PSA and digital rectal exam screening.
Representative report page — not an actual patient result.
Important considerations
What this test can and cannot tell you
This test is a screening tool, not a diagnostic test.
This test does not detect high-risk variants linked to monogenic conditions.
The Integrated Risk test is intended as a screening tool — some people with a high risk score will not develop prostate cancer and some with a low risk score will.
Map your risk, guide lifelong health.
We're here at every step — from ordering and sample collection to interpreting results with your patients.